Drug Profile


Alternative Names: Interleukin-4 diphtheria toxin chimeric protein; Interleukin-4 fusion toxin

Latest Information Update: 14 Feb 2001

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Nonindustrial source; Seragen
  • Class Interleukins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer; Graft-versus-host disease; Hypersensitivity; Leukaemia; Lymphoma

Most Recent Events

  • 14 Feb 2001 Discontinued-Preclinical for Lymphoma in USA (Unknown route)
  • 14 Feb 2001 Discontinued-Preclinical for Allergy in USA (Unknown route)
  • 14 Feb 2001 Discontinued-Preclinical for Leukaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top